So first the “less good” news … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer | Tagged: OPKO, point of care, PSA, Sangia, test | 5 Comments »
-
-
-
-
-
-
- The "New" Prostate Cancer InfoLink has been developed to become a primary source of accurate, current, and topical information about prostate cancer for patients and their families.
A service of
Awards
Other PCI web sites
-
PCaI’s ASVSG
If you are on or thinking about active surveillance (AS) as a way to manage your low-risk prostate cancer, you may want to join Prostate Cancer International’s Active Surveillance Virtual Support Group.
CureTalks on PCa
Our most recent CureTalk on Prostate Cancer (on February 21 this year) features Eli Van Allen, MD, of the Broad Institute and the Dana-Farber Cancer Center, talking about the new “Metastatic Prostate Cancer Project” and how you can become part of the solution.
For access to the full list of CureTalks on Prostate Cancer, please click here.
Disclaimer
News and information provided on this site should not be used for diagnosing or treating any health problem or disease.
The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.
-
Hot Posts …
- Long-term follow-up data from LATITUDE trial
- Germline genetic testing for men with prostate cancer
- The use of the word “survivor” can arouse strong feelings
- Does TRT really delay biochemical recurrence after radical prostatectomy (in selected patients)?
- Agent Orange and prostate cancer-specific survival on ADT
- No mortality benefit from dietary supplements … says Harvard and Tufts
- FDA approves new type of PSA testing methodology
- Next-generation imaging in the management of advanced prostate cancer
- Curing mice with prostate cancer!
- Restore – a clinical trial for MsM with prostate cancer
- “To DRE or not to DRE, that is the question”
- For those considering treatment with a checkpoint inhibitor
- Phase III trial of olaparib in first-line treatment of mCRPC
- New prostate cancer imaging techniques and their use in clinical practice
- Darolutamide (ODM-201) in the treatment of nmCRPC
… and Archives
Blog at WordPress.com. WP Designer.
